Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
  • A61K38/046—Tachykinins, e.g. eledoisins, substance P; Related peptides
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals

Definitions

• Newcastle disease Newcastle disease
• Other respiratory viruses affecting fowl include infectious bronchitis virus and avian pneumovirus. While these effects are felt economically by producers and consumers, they also present public health issues. Birds are thought to provide a reservoir for viruses that infect human populations.
• a method for preventing respiratory viral infections in domestic fowl An effective amount of an agent in admixture with feed is administered to domestic fowl.
• the agent is selected from the group consisting of: substance P, [Met-OH 1 ⁇ -substance P, [Met-OMe"]-substance P, [NIe"] -substance P, [Pro 9 ] -substance P, [Sar ⁇ -substance P, [Tyr 8 ]-substance P, Sar 9 , Met (O 2 ) 11-Substance P, and [p-Cl-Phe 7>8 ] -substance P.
• the infection rate is decreased by means of the administration..
• Au effective amount of an agent in an aerosol is administered to domestic fowl.
• the agent is selected from the group consisting of: substance P, [Met-OH 1 ⁇ -substance P, [Met-OMe"]-substance P, [Nle n ]-substance P, [Pro 9 ] -substance P, [Sar 9 ]-substance P, [Tyr 8 ] -substance P, Sar 9 , Met (O 2 ) 11 -Substance P, and [p-Cl-Phe 7 ' s ]-substance P.
• the rate of infection is decreased by the administration..
• Another method for preventing respiratory viral infections in domestic fowl is provided.
• An effective amount of an agent is administered to domestic fowl.
• the agent is selected from the group consisting of: substance P, [Met-OH U ] -substance P, [Met-OMe"]-substance P, [Nle ⁇ ]-substance P, [Pro 9 ]-substance P, [Sar 9 ]-substance P, [Tyr 8 ]-substance P, Sar 9 , Met (O 2 ) 11- Substance P, and [p-Cl-Phe 7>8 ]-substance P.
• the mode of administration is selected from the group consisting of intramuscular, intravenous, intrabronchial, sublingual, intratracheal, and subcutaneous. The rate of infection is decreased by the administration.
• Substance P and its bioactive analogs are beneficial preventatives against respiratory virus infections in domestic fowl.
• Substance P and its analogs potentiate the lung's immune response against respiratory viruses.
• Substance P and its analogs can be used to prophylactically treat poultry to minimize infection and to minimize spread of infection between birds and to other species, including humans.
• the bioactive analog can be selected from the group consisting of [Met-OH 1 ⁇ -substance P, [Met-OMe 11 ] -substance P, [Nle"]-substance P, [Pro 9 ]-substance P, [Sar 9 ]-substance P, [Tyr s ]-substance P, Sar 9 , Met (O 2 ) 11- Substance P, and [p-Cl-Phe 7 ' 8 ] -substance P.
• Other compounds which function in the same way can be identified by their ability to compete with substance P for binding to its receptor (NK-I) or for their ability to agonize the NK-I receptor. Routine assays for such activities are known in the art and can be used.
• the substance P or analog can be administered by any method known in the art, including via aerosol inhalation and via admixture with feed. Intravenous, intratracheal, intrabronchial, intramuscular, sublingual, and oral administrations can also be used. Preferred dosages include 0.05 to 5 nanomolar substance P or analog for intravenous administration, preferably 0.1 to 2 nanomolar, and more preferably 0.5 to 1.5 nanomolar. For aerosol administration dosages include 0.05 to 75 micromolar substance P or analog, preferably 0.1 to 2 micromolar, and more preferably 0.5 to 1.5 micromolar. Typical concentration ranges of substance P or its bioactive analog in the aerosol administered is between 0.001 and 10 ⁇ M. It can be advantageously administered as a liquid at a concentration between about 0.1 and 10 ⁇ M.
• Bioactive analogs are those which act as competitive inhibitors of SP by binding to the SP receptor (NK-I receptor).
• the analogs may be agonists of the NK-I receptor.
• Other derivatives as are known in the art and commercially available (e.g., from Sigma) can be used.
• substance P fragments and derivatized substance P fragments may also be used. Substitution, deletion, or insertion of one to eight amino acid residues, and preferably from one to three amino acid residues, will lead to analogs which can be routinely tested for biological activity.
• functional groups may be modified on SP while retaining the same amino acid backbone. Again, routine testing will determine which of such modifications do not adversely affect biological activity.
• Suitable devices for administering the aerosol of the present invention include nebulizers as well as hand-held aerosol "puffer” devices.
• Suitable treatment regimens for treatment according to the present invention include one-time, monthly, weekly, daily or multiple daily treatment by aerosol. Frequency may depend on the immediate risk of infection in a geographical area at a particular time.
• Other modes of treatment include continual transdermal infusion; intravenous, intramuscular, sublingual, and subcutaneous injections; and oral administration.
• Suitable formulations of substance P for administration are any which are veterinarially acceptable and in which the substance P or bioactive analog retains its biological activity. Generally, such formulations are substance P dissolved in normal saline, which is optionally sterile.
• Other formulations for changing absorption and half-life characteristics can be used, including liposomal formulations and slow-release formulations.
• Disease features of respiratory viral infections include Clara cell necrosis, increased pulmonary alveolar macrophage number, neutrophil number, alveolar- capillary barrier membrane damage, surfactant depletion, and increased 6-keto-PGFi ⁇ and PGE 2 concentrations. These disease features are reduced in a population by the prophylactic administrations of the present invention. Decreases in the disease features or rates of infection in a population of at least 10 %, 15 %, 20 %, 25%, 30 %, 35 %, 40 %, or 50 % are desirable. Even greater decreases are preferred.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Chemical & Material Sciences (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• General Chemical & Material Sciences (AREA)
• Communicable Diseases (AREA)
• Organic Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Oncology (AREA)
• Gastroenterology & Hepatology (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Epidemiology (AREA)
• Immunology (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Virology (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
• Medicinal Preparation (AREA)
• Peptides Or Proteins (AREA)

Applications Claiming Priority (2)

Publications (2)

Family

ID=36647801

Family Applications (1)

Country Status (6)

Families Citing this family (1)

Family Cites Families (2)

• 2005
  • 2005-01-27 SG SG200500467A patent/SG123646A1/en unknown
  • 2005-11-23 EP EP05849894A patent/EP1838216A4/de not_active Withdrawn
  • 2005-11-23 JP JP2007549376A patent/JP2008526741A/ja active Pending
  • 2005-11-23 CA CA002593232A patent/CA2593232A1/en not_active Abandoned
  • 2005-11-23 WO PCT/US2005/042601 patent/WO2006073603A1/en active Application Filing
  • 2005-11-23 AU AU2005323304A patent/AU2005323304A1/en not_active Abandoned

Non-Patent Citations (2)

Also Published As

Similar Documents

Legal Events